---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-076412"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:47:59.901869+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Liquidia reports Q2 2025 results: YUTREPIA launch drives $6.5M product revenue, net loss widens

## Summary
- YUTREPIA (treprostinil) inhalation powder approved by FDA May 23, 2025; commercial launch in June 2025.
- Over 900 unique patient prescriptions and 550 patient starts within 11 weeks post-approval.
- ASCENT trial interim: median 6MWD improvement 31.5m at Week 16; median dose 159 mcg QID; no drug-related discontinuations.
- Cash $173.4M as of June 30, 2025; product revenue $6.5M in Q2 2025 (first YUTREPIA sales).
- Net loss $41.6M ($0.49 per share) vs $28.7M ($0.38) in Q2 2024; SG&A up 95% on commercialization and litigation.

## SEC filing metadata
- accession: 0001104659-25-076412
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465925076412/0001104659-25-076412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465925076412/tm2523179d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-076412
- JSON: https://secwatch.observer/filing/0001104659-25-076412.json
- Plain text: https://secwatch.observer/filing/0001104659-25-076412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.